Recombinant Human CD39/ENTPD1 Protein, CF Summary
Product Specifications
Thr38-Val478, with a C-terminal 6-His tag
Analysis
Customers also Viewed
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
4397-EN
| Formulation | Supplied as a 0.2 μm filtered solution in Tris, NaCl, CaCl2 and Glycerol. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 25 mM Tris, 5 mM CaCl2, pH 7.5
- Recombinant Human CD39/ENTPD1 (rhCD39) (Catalog # 4397-EN)
- Substrate: ATP (Sigma, Catalog # A-7699), 10 mM stock in deionized water
- Malachite Green Phosphate Detection Kit (Catalog # DY996)
- 96-well Clear Plate (Costar, Catalog # 92592)
- Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
- Dilute rhCD39 to 0.04 µg/mL in Assay Buffer.
- Prepare a standard curve from the 1 M Phosphate Standard supplied in the malachite green phosphate detection kit. First, add 10 µL of the 1 M Phosphate Standard to 990 µL of Assay Buffer for a 10 mM stock. Then, add 10 µL of the 10 mM phosphate stock to 990 µL of Assay Buffer for a 100 µM stock. (This is the first dilution to use as a standard.) Finally, perform six additional two-fold serial dilutions of the 100 µM phosphate stock. The standard curve has a range of 0.039 to 2.5 nmol per well.
- Transfer to a 96 well clear plate (in duplicate) 25 µL of diluted rhCD39 at 0.04 µg/mL, standard curve, and blanks (Assay Buffer).
- Dilute Substrate to 100 µM in Assay Buffer.
- Add 25 µL of the diluted Substrate to all wells. Mix well.
- Cover the plate with parafilm or a plate sealer and incubate at 37 °C for 30 minutes.
- After incubation, add 10 µL of the Malachite Green Reagent A to each sample, standard, and blank. Mix and incubate for 10 minutes at room temperature.
- Add 10 µL of the Malachite Green Reagent B to each sample, standard, and blank. Mix and incubate for 20 minutes at room temperature.
- Read plate at 620 nm (absorbance) in endpoint mode.
- Calculate specific activity:
|
Specific Activity (pmol/min/µg) = |
Phosphate released* (nmol) x (1000 pmol/1 nmol) |
| Incubation time (min) x amount of enzyme (µg) |
*Derived from the phosphate standard curve using linear or 4-parameter fitting and adjusted for Substrate Blank.
Per Well:- rhCD39: 0.001 µg
- Substrate: 35.7 µM
Background: CD39/ENTPD1
Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase-1) is an integral membrane protein with an extracellular active site. Recombinant human NTPDase-1 was expressed as a protein lacking its N- and C-terminal transmembrane domains, resulting in the secretion of the soluble recombinant human NTPDase-1 ectodomain. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker (2), but it is also present on the surface of natural killer cells, T cells, and some endothelial cells (3). NTPDase-1 hydrolyzes the beta - and gamma phosphate residues of nucleotides, preferring ATP as the substrate. Through its hydrolysis of extracellular nucleotides, NTPDase-1 plays a role in the regulation of purinergic signaling (4). NTPDase-1 is involved in the processes of thromboregulation and vascular inflammation (5). The administration of soluble NTPDase-1 may have therapeutic applications for the treatment of some vascular and transplantation-associated diseases (6).
- Maliszewski, C.R. et al. (1994) J. Immunol. 153:3574.
- Rowe, M. et al. (1982) Int. J. Cancer 29:373.
- Kansas, G.S. et al. (1991) J. Immunol. 146:2235.
- Kishore, B.K. et al. (2005) Am. J. Physiol. Renal Physiol. 288:F1032.
- Marcus, A.J. et al. (2005) Semin. Thromb. Hemost. 31:234.
- Robson, S.C. et al. (2005) Semin. Thromb. Hemost. 31:217.
Citations for Recombinant Human CD39/ENTPD1 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Assessment of ATP Metabolism to Adenosine by Ecto-Nucleotidases Carried by Tumor-Derived Small Extracellular Vesicles
Authors: Hong, CS;Menshikova, EV;Whiteside, TL;Jackson, EK;
Research square
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Human soluble CD39 displays substrate inhibition in a substrate-specific manner
Authors: Vadlamani, VMK;Gunasinghe, KKJ;Chee, XW;Rahman, T;Harper, MT;
Scientific reports
Species: Human
Sample Types:
Applications: Bioassay -
Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression
Authors: R Muñóz-Godí, M de Lourdes, B Weiss-Stei, JJ Montesinos, A Del Carmen, R García-Roc, J Hernández-, C Azucena Do, LR Ávila-Ibar, DB Torres-Pin, G Molina-Cas, R Chacón-Sal, L Vallejo-Ca, SM Pérez-Tapi, A Monroy-Gar
Mediators of Inflammation, 2020-12-07;2020(0):1678780.
Species: Human
Sample Types: Reference Standard
-
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
Authors: I Perrot, HA Michaud, M Giraudon-P, S Augier, A Docquier, L Gros, R Courtois, C Déjou, D Jecko, O Becquart, H Rispaud-Bl, L Gauthier, B Rossi, S Chanteux, N Gourdin, B Amigues, A Roussel, A Bensussan, JF Eliaou, J Bastid, F Romagné, Y Morel, E Narni-Manc, E Vivier, C Paturel, N Bonnefoy
Cell Rep, 2019-05-21;27(8):2411-2425.e9.
Species: Human
Sample Types: Protein
Applications: ELISA Capture -
HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1
Authors: M de Lourdes, S López-Cisn, V Gutiérrez-, R García-Roc, B Weiss-Stei, J Hernández-, HI Sánchez-Pe, LR Ávila-Ibar, CA Don-López, R Muñóz-Godí, DBT Pineda, R Chacón-Sal, L Vallejo-Ca, SM Pérez-Tapi, A Monroy-Gar
Mediators Inflamm., 2019-05-07;2019(0):4651627.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA -
ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions
Authors: H Degen, O Borst, M Ziegler, AK Mojica Mun, J Jamasbi, B Walker, S Göbel, J Fassbender, K Adler, R Brandl, G Münch, R Lorenz, W Siess, M Gawaz, M Ungerer
J Am Heart Assoc, 2017-07-27;6(8):.
Species: Mouse
Sample Types: In Vivo, Protein
Applications: Enzyme Assay, In Vivo -
The ubiquitin ligase ASB4 promotes trophoblast differentiation through the degradation of ID2.
Authors: Townley-Tilson, W H Davi, Wu, Yaxu, Ferguson, James E, Patterson, Cam
PLoS ONE, 2014-02-21;9(2):e89451.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsPhosphatase Activity Assays
Reviews for Recombinant Human CD39/ENTPD1 Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human CD39/ENTPD1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
dose response in reporter cells
